If you have been reading about HPLC-UV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-05. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Melitta Schmideberg-Klein (née Klein; 17 January 1904 – 10 February 1983), author of numerous books, academic papers and monographs; physician, psychiatrist, and psychoanalyst; daughter of leading psychoanalyst Melanie Klein; associate member of British Psychoanalytical Society and underwent analysis with Edward Glover, Hanna Segal (1918–2011), psychoanalyst of Polish Jewish descent; follower of Melanie Klein; president of British Psychoanalytical Society, vice-president of International Psychoanalytical Association; was appointed to the Freud Memorial Chair at University College, London (UCL); considered the doyen of "classical" Kleinian thinking and technique" and "one of the most distinguished psychological theorists of our time " Judah Segal, FBA (21 June 1912 – 23 October 2003, prolific author, scholar and academic; Professor of Semitic Languages at the School of Oriental and African Studies.His father was Professor Moshe Zvi Segal, Israeli rabbi, linguist and Talmudic scholar; his brother was Labour Party politician Samuel Segal; father of University of London scholar, Professor Naomi Segal. Lynne Segal (born 29 March 1944) socialist feminist academic and activist; author of over ten books and numerous scholarly monographs on ideology and geopolitics; Professor of Psychology and Gender Studies at Birkbeck, University of London, where she now works in The School of Psychosocial Studies.
=== Differentiation === CAFs can also be derived from differentiation of other cell types such as mesenchymal stem cells, which was proved in murine models with cancers such as glioma, breast, pancreatic and gastric cancers. Another suggested origin is differentiation of endothelial or epithelial cells via trans-differentiation or epithelial to mesenchymal transition, respectively. Less common origin of CAFs is by differentiation of other tumor adjacent cells such as epithelial or endothelial cells, adipocytes, pericytes and smooth muscle cells. Adipocytes, especially white adipocytes transdifferentiate into CAFs upon activation with TGF-β1. Through TGF-β1 can be transformed also peritoneal mesothelial cells. It has been suggested that CAFs are better conceptualised as a “cell state” Research has found that CAF trans-differentiation can be caused by epigenetic factors.
== History == The first 15 years of the EIP focused on establishing vaccination schedules and ensuring that poorer countries had a supply of vaccines. In 1974, only 5% of children in low-income countries and 21% of all children received basic vaccines. DTP3 coverage increased from 20% in 1982 to 76% in 1990. (DTP3 refers to the third shot of the DTP vaccine. DTP3 completion rates in one-year-olds is used as a proxy for infant vaccination completion rates.) The growth was fueled by Child Survival and Development Revolution initiated by Jim Grant in UNICEF. After the sharp increase in vaccination rates, the growth has slowed to a halt because the most of the remaining infants live in places where the cold chain for vaccine storage is unreliable. In response the EPI broadened its scope and introduced more vaccines (HepB, Hib, PCV) into schedules. This expands the spectrum of protection for kids with access to vaccines. The GAVI was founded in 2000, providing funding for expanding vaccine access in poorer countries. The DTP3 completion rate was 83% by 2010. Technical innovations such as the solar-powered refrigerator and the vaccine vial monitor played a large role in gaining the 7 percentage points. In the one-and-a-half decades after 2010, the EPI saw major achievements including the appearance and endorsement of rotavirus, HPV, and malaria vaccines. The rotavirus vaccine greatly reduced women and child mortality due to diarrhea; the HPV vaccine had already made a dent in the number of cervical cancer cases; and the malaria vaccine too has saved lives.
Every case is different, and different embalming professionals work in different ways. Common grooming practices may include combing and styling the hair and applying cream or emollient spray to the skin to maintain hydration. The deceased will then be dressed and makeup may be applied to mimic natural coloring or the deceased person's typical styling. Hair gel or baby oil is applied to style short hair; while hairspray is applied to style long hair. Powders (especially baby powder) are applied to the body to eliminate odors, and it is also applied to the face to achieve a matte and fresh effect to prevent oiliness of the corpse. Makeup techniques may include using an airbrush to evenly apply product, using mascara to add volume to eyelashes, filling in eyebrows with pencil, and using lipstick or gloss to add color to the lips. Mortuary cosmeticizing is not done for the same reason as make-up for living people; rather, it is designed to add depth and dimension to a person's features that lack of blood circulation has removed. Warm areas – where blood vessels in living people are superficial, such as the cheeks, chin, and knuckles – have subtle reds added to recreate this effect, while browns are added to the palpebrae (eyelids) to add depth, especially important as viewing in a coffin creates an unusual perspective rarely seen in everyday life. During the viewing, pink-colored lighting is sometimes used near the body to lend a warmer tone to the deceased's complexion.
=== Activation by pH === Acidic conditions can denature the LAP. Treatment of the medium with extremes of pH (1.5 or 12) resulted in significant activation of TGF-β as shown by radio-receptor assays, while mild acid treatment (pH 4.5) yielded only 20-30% of the activation achieved by pH 1.5.
Sources: en.wikipedia.org
Lymph contains cellular debris, bacteria, proteins, and lymphocytes, the latter of which are generated largely in the bone marrow and matured or activated in the lymph nodes, spleen, thymus, and tonsils. Lymph also transports antigen-presenting cells, such as dendritic cells, to the lymph nodes where an immune response is stimulated. B cells and T cells are the major types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. From the bone marrow, B cells immediately join the circulatory system and travel to secondary lymphoid organs in search of pathogens. T cells, on the other hand, travel from the bone marrow to the thymus, where they develop further, mature, and become immunocompetent. In the thymus, T cells are exposed to a wide variety of self-antigens; T cells can only recognize a "non-self" target only after antigens have been processed and presented in combination with the major histocompatibility complex (MHC) self-receptor. In contrast, the B cell antigen-specific receptor is an antibody molecule on the B cell surface, recognising unprocessed antigens (e.g. large molecules found on the surfaces of pathogens; small haptens, such as penicillin, attached to carrier molecules) without any need for antigen processing. Each lineage of B cell expresses a different antibody, so the complete set of B cell antigen receptors represents all the antibodies that the human body can manufacture. The secondary (or peripheral) lymphoid organs (e.g.
The team under Wenger's management enjoyed another relatively strong league campaign in 2004–05, but finished second to Chelsea, who ended the season 12 points in front. Consolation again came in the FA Cup; Arsenal defeated Manchester United on penalties, after a goalless final. The emergence of Cesc Fàbregas in the starting line-up prompted Wenger to sell Vieira to Juventus in July 2005. He noticed the two as a midfield pairing was ineffective, and felt keeping Fàbregas would benefit the club's future. The 2005–06 season marked the beginning of a transitional period for Arsenal as it was the club's final season at Highbury. The team finished fourth in the Premier League and outside the top two for the first time under Wenger's tenure. In the Champions League, Wenger assembled an inexperienced defence that reached the final, beating Real Madrid, Juventus and Villarreal and conceding no goals in the knockout stages. In the final against Barcelona in May 2006, Arsenal took an early lead but ultimately lost the match 2–1. The defeat also made Wenger the only manager to have been a losing finalist in each of UEFA's three main club competitions, having previously lost the UEFA Cup final with Arsenal in 2000 and the Cup Winners' Cup final with Monaco in 1992.
=== Extraction === After cooking, the alkaline liquid (known as nejayote from Nahuatl nexayotl - nextli 'ash' y ayotl 'liquid'), containing dissolved hull, starch, and other corn matter, is decanted and discarded (or sometimes used for making amate bark paper). The kernels are washed thoroughly of remaining nejayote, which has an unpleasant flavor. The pericarp is then removed, leaving the endosperm of the grain with or without the germ, depending on the process. This hulling is performed by hand, in traditional or very small-scale preparation, or mechanically, in larger scale or industrial production. The prepared grain is called hominy, mote, or nixtamal. Nixtamal has many uses, contemporary and historic. Whole nixtamal may be used fresh or dried for later use. Whole nixtamal is used in the preparation of pozole, menudo, and other foods. Ground fresh nixtamal is made into masa (nixtamal dough) and used to make tortillas, tamales, and pupusas. Dried and ground, it is called masa harina or instant masa flour, and is reconstituted and used like masa. The term hominy may refer to whole, coarsely ground, or finely ground nixtamal, or to a cooked porridge (also called grits) prepared from any of these. Samp is similar to grits, but a product of a different process.
=== Evasive strategies === Algae may resist algicidal bacteria through evasive strategies, such as forming morphologically distinct resting stages. These resting stages can help algae avoid direct contact with algicidal bacteria and survive unfavourable conditions. When the conditions improve, the resting stages can germinate and re-establish growing populations.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.